Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal pharmacokinetic bioequivalance study of PUR-0200 (Tiotropium-bromide)

Trial Profile

A pivotal pharmacokinetic bioequivalance study of PUR-0200 (Tiotropium-bromide)

Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 08 Aug 2017 New trial record
    • 04 Aug 2017 According to a Pulmatrix media release, data from this trial will support an European product registration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top